(NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million people worldwide are diagnosed with epilepsy, and seizures are the main ...

This transcript has been edited for clarity. Andrew N. Wilner, MD: Welcome to Medscape. I'm your host, Dr Andrew Wilner, reporting on the annual American Epilepsy Society meeting. With me today is my ...

Absence seizures are thought to, at least in part, be caused by abnormal neuron firing between the thalamus and the cortex. For unknown reasons, neurons in these two brain regions become ...

Absence seizures, common in children, present as brief lapses in awareness, often mistaken for daydreaming. These non-convulsive seizures involve staring spells and subtle movements, potentially ...

Researchers have gained new insights into the cellular and molecular mechanisms of absence seizures and potential therapy options. Stimulation of certain cerebellar areas could help combat absence ...

Imagine slipping in and out of consciousness hundreds of times per day, staying awake the whole time but having no sense of awareness during these lapses. In children with absence epilepsy, these ...

Bochum researchers have gained new insights into the cellular and molecular mechanisms of absence seizures and potential therapy options. Stimulation of certain cerebellar areas could help combat ...

A particular structure in the brain is a "choke point" for a type of epileptic seizure that affects mostly children, Stanford University School of Medicine investigators have found. The researchers ...

More than 3.4 million people in the United States have epilepsy, so it is a relatively common diagnosis. In fact, it is the fourth-most common neurologic condition in the world. November is National ...

Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% ...

Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...